(Q84147482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

main subject

cervix uterine cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

4

Chris J L M Meijer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

H E de Melker

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Peter J F Snijders

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Johannes Berkhof

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

28 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

5111-5119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Non-progression of cervical intraepithelial neoplasia estimated from population-screening data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

An introduction to Markov modelling for economic evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

High-risk HPV type-specific clearance rates in cervical screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

HPV16 and increased risk of recurrence after treatment for CIN.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Benefits and costs of using HPV testing to screen for cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Care and costs for advanced cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.06.043

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.06.043

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19567242%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference